Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274568 · ClinicalTrials.gov registry record · Phase 1
Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
A Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05274568: Completed Phase 1 study, sponsored by Invicro.
NCT05274568 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05274568, a Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to: Evaluate \[18F\]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: • Confirm a specific α -synuclein signal with \[18F\]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers Secondary and exploratory objectives are: * Determine the safety and tolerability of microdose \[18F\]UCB-2897 * Evaluate preliminary dosimetry of \[18F\]UCB-2897 Additional exploratory objectives are: * Determine the pharmacokinetics / metabolism of \[18F\]UCB-2897 * Determine the optimal imaging protocol for \[18F\]UCB-2897
Primary Outcome
\[18F\]UCB-2897 uptake and kinetics will be examined in the MSA, PD, and healthy volunteer groups descriptively and quantitatively to describe the α-synuclein deposition as measured by \[18F\]UCB-2897 across multiple brain regions.
Interventions
- DRUG [18F]UCB-2897
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2023-10-25 |
| Phase | Phase 1 |
What the finished NCT05274568 record still lists
NCT05274568 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]UCB-2897 is the first listed.
NCT05274568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05274568 about?
NCT05274568 is a clinical study titled "Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein". The overall goal of this protocol is to: Evaluate \[18F\]UCB-2897 as an α-synuclein targeted radiopharmaceutical. The primary objective is: • Confirm a specific α -synuclein signal with \[18F\]UCB-2897 in participants with PD and/or MSA relative to healthy volunteers Secondary and exploratory ob...
What is the current status of trial NCT05274568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2022-01-31. Estimated completion is 2023-10-25.
What interventions are being tested in trial NCT05274568?
The interventions under investigation include: [18F]UCB-2897 (DRUG).
Who is sponsoring clinical trial NCT05274568?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05274568's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI